To investigate the combined effects of a PIM‐2 inhibitor and a PARP1 inhibitor on apoptosis and tumor growth in multiple myeloma (MM) cells in vivo, NSG mice were subcutaneously injected with 1 × 107 RPMI‐8226 cells to establish a myeloma model. This evidence concerns the gene PARP1 and neoplasm.